Ibogaine Legal Status

United States: Schedule I

Ibogaine has been classified as a Schedule I controlled substance in the United States since 1967. This means it cannot be legally prescribed, manufactured, or used for treatment within the US. Schedule I classification also severely restricts research — creating a Catch-22 where the evidence needed to change the scheduling is difficult to generate because of the scheduling itself.

Mexico: Legal and Unregulated

In Mexico, ibogaine is not classified as a controlled substance. It is unregulated, meaning clinics can legally operate and provide ibogaine treatment. This legal environment, combined with Mexico's proximity to the United States, has made it the world's primary destination for ibogaine therapy.

The Legislative Momentum

The political landscape around ibogaine is shifting rapidly:

• Texas (2025): $50 million committed to ibogaine research — the largest state-funded psychedelic research program in history, aimed specifically at FDA clinical trials
• Arizona (2025): $5 million allocated for Phase I clinical trials
• Kentucky and Washington State: Legislative proposals for psychedelic therapy research
• VA Research Expansion: 9 VA facilities conducting psychedelic therapy trials for the first time

The FDA Pathway

Ibogaine qualifies for Breakthrough Therapy designation from the FDA, which would expedite the review process. The Texas initiative is specifically aimed at achieving Investigational New Drug (IND) approval and eventually conducting the Phase II and Phase III clinical trials needed for FDA approval. If successful, ibogaine could become a legally prescribed treatment in the US within the next 5-10 years.

Other Countries

• New Zealand: Ibogaine is available as a prescription medicine
• Brazil: Legal in clinical settings in some states
• Netherlands: Available in specific clinics
• Canada: Available through the Special Access Program in some cases